Drug Profile
DRGT 104
Alternative Names: DRGT-104Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Developer Tavanta Therapeutics
- Class
- Mechanism of Action Esterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Unspecified in Hungary (unspecified route)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Unspecified in Hungary
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics